Active Biotech and Teva together in a Phase II clinical trial against Huntington’s disease

Active Biotech

Active Biotech announced today that its partner Teva Pharmaceutical will initiate a phase II clinical trial to evaluate the efficacy and safety of oral laquinimod for the treatment of Huntington’s disease.

Laquinimod is a once-daily oral, investigational, CNS-active immunomodulator with a novel mechanism of action being developed primarily for the treatment of relapsing-remitting multiple sclerosis (RRMS) and progressive forms of multiple sclerosis. In extensive non-clinical and clinical studies, laquinimod has demonstrated both anti-inflammatory and neuroprotective properties and effects that have been shown to provide clinically meaningful results.

Active Biotech is a biotechnology company with focus on autoimmune/inflammatory diseases and cancer. Tasquinimod another Active Biotech’s drug, for the treatment of prostate cancer, is in pivotal phase. In addition, laquinimod has concluded Phase II development for Crohn’s and Lupus. The company has two additional projects in clinical development: Anyara, primarily for the treatment of renal cell cancer and the orally administered compound paquinimod for systemic sclerosis.

Newsletter Signup - Under Article / In Page

"*" indicates required fields

Subscribe to our newsletter to get the latest biotech news!

This field is for validation purposes and should be left unchanged.

Suggested Articles

Show More